ION BIOSCIENCES

Specifications

CHO-K1 K_V11.1 (hERG) Recombinant cell line

Catalog No. C1202

Introduction

Voltage-gated potassium channels (K_V) are transmembrane channels specific for potassium and sensitive to voltage changes in the cell's membrane potential. All mammalian K_V channels consist of four α-subunits, each containing six transmembrane α helical segments S1-S6 and a membrane-reentering P-loop, which are arranged circumferentially around a central pore. The human genome contains 40 voltage-gated potassium channels, which are classified into 12 subfamilies, K_V1-K_V12. K_V channels are involved in diverse physiological processes ranging from repolarization of neuronal or cardiac action potential, over regulating calcium signaling and cell volume, to driving cellular proliferation and migration. Thus, K_V channels offer tremendous opportunities for the development of new drugs for cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders.

Recombinant CHO-K1 K_V11.1 (hERG) cell line expresses human KCNH2 (voltage-gated potassium channel subfamily H member 2, accession number NM_000238). K_V11.1 channels are abundantly expressed in the heart and brain. In the heart, Kv11.1 channels plays a crucial role in repolarization of the cardiac action potential; inhibition of K_V11.1 current due to genetic mutations or channel inhibitors causes drug-induced long QT syndrome, a potential fatal cardiac arrhythmia. K_V11.1 can be blocked by a large variety of structurally diverse compounds, thus the FDA requires that all new drug candidates are tested for potential K_V11.1 inhibition. Besides its relevance in cardiac physiology, K_V11.1 channels are also linked to schizophrenia, tumor cell proliferation, regulation of cell migration and apoptosis. Our CHO-K1 Kv11.1 (hERG) cell line is suitable for discovering modulators of Kv11.1 channel activity and screening for Kv11.1 activator/inhibitor in high-throughput platforms.

Materials Provided

One vial of CHO-K1 Kv11.1 (hERG) recombinant cells, 2×10^6 cells in 1 mL of Bambanker serum free freezing medium.

Storage

Cells are shipped on dry ice and should arrive frozen. To ensure maximum cell viability, store the cell vial in liquid nitrogen immediately upon receipt.

Mycoplasma testing

The cell line has been screened using ATCC PCR-based testing service which covers 60 species of *Mycoplasma, Acholeplasma, Spiroplasma* and *Ureaplasma* including the eight species most likely to afflict cell cultures: *M. arginini, M. fermentans, M. hominis, M.hyorhinis, M. orale, M. pirum, M. salivarium,* and *A. laidlawii.* The absence of Mycoplasma species has been confirmed for each lot. For detailed verification, please see the product certificate of analysis.

Materials Required But Not Supplied

Category	Name	Recommendations
Reagents	Cell culture media	Advanced MEM (ThermoFisher Cat#: 12491013)
	GlutaMax™	GlutaMAX™ Supplement (ThermoFisher Cat#: 35050061)
	Fetal bovine serum (FBS)	Fetal Bovine Serum (Corning Cat#: 35-016-CV)
	Puromycin	Puromycin Dihydrochloride (ThermoFisher Cat#: A1113803)
	TrypLE™	TrypLE™ Express Enzyme (ThermoFisher Cat#: 12605028)
	Phosphate buffered saline	PBS, pH 7.4 (ThermoFisher Cat#: 10010023)
	Freezing media	Bambanker Serum Free Cell Freezing Medium
Equipment	Single and multichannel micropipettes and pipette tips	
	50 mL and 15 mL conical centrifuge tubes	
	1.5 mL microtubes	
	Tissue culture disposable pipettes (1 mL-25 mL) and tissue culture flasks (e.g. T75 flask)	
	0.2 µm filter unit for medium sterilization	
	Cryovials for freezing cells	
	Automated Cell Counter (or Hemocytometer)	
	Humidified tissue culture incubator (37°C and 5% CO_2)	

Cell Culture Protocol

A. Cell culture media

1. Make thawing medium by combining 25 mL of FBS, 5 mL of 100X GlutaMax with 470 mL 1X Advance MEM media for the final concentration of 5% FBS and 1X GlutaMax.
2. To make complete culture medium, add 150 µL of 10 mg/mL Puromycin into 500 mL of medium from **step 1** for the final concentrations of 3 µg/mL Puromycin.
3. (Optional) Sterilize all media using 0.2 µm filter.
4. Pre-warm all media in a 37°C water bath prior to use.

B. Thawing cells

1. Aliquot 8 mL of thawing medium in a 15 mL conical centrifuge tube.
2. Place the cryovial in a 37°C water bath briefly, until only small ice crystals remain and the cell pellet is almost completely thawed. The thawing time typically ranges from 2 to 3 minutes. Do **NOT** vortex freshly thawed cells.
3. Spray and wipe the external surface of the cryovial with 70% ethanol. Transfer the vial to a biosafety cabinet.
4. Gently add the cells into the pre-filled 15 mL conical tube dropwise.
5. Rinse the cryovial with 1 mL of thawing medium to maximize cell recovery and add it back into the 15 mL conical tube.

Cell Culture Protocol Cont.

6. Centrifuge the 15 mL conical tube containing cells at 500xg for 5 min at 25°C.
7. Add 14 mL of complete cell culture medium into a T75 flask.
8. After centrifugation, carefully aspirate the supernatant without disturbing the cell pellet.
9. Gently resuspend the cell pellet with 1 mL of complete cell culture medium.
10. Transfer the cell suspension to the T75 flask and gently swirl the flask to distribute the cells evenly in solution.
11. Incubate the flask in a 37°C and 5% CO_2 humidified cell culture incubator.
12. Maintain the cells in culture by changing culture media every 2-3 days, until they reach >80% confluency in a T75.

C. Cell passage

1. Remove the T75 flask from the tissue culture incubator and place it in a biosafety cabinet.
2. Gently aspirate the media from the T75 flask.
3. Add 15 mL of PBS into the T75 flask, and gently rock the flask back and forth to rinse the cells.
4. Gently aspirate PBS from the flask.
5. Add 3 mL of pre-warmed TrypLE to the flask. Gently rock the flask back and forth to ensure that the flask is uniformly covered with TrypLE.
6. Incubate the flask at 37°C and 5% CO_2 until the cells have detached. Usually it will take 8 - 10 min.
7. Remove the flask from the incubator and observe the cells under a microscope to confirm cell detachment. If necessary, gently tap the edge of the flask to detach cells from the surface.
8. Add 10 mL of pre-warmed complete cell culture media to the detached cells in the flask.
9. Transfer cell suspension into a 15 mL conical tube.
10. Centrifuge the 15 mL conical tube containing cells at 500xg for 5 min at 25°C.
11. After centrifugation, carefully aspirate the supernatant without disturbing the cell pellet.
12. Resuspend the cell pellet with 5 mL of complete cell culture medium. Pipette the cell suspension up and down several times to generate a single cell suspension without any clumps.
13. Take a small aliquot of the cell suspension (~20 µL) for cell counting, and determine the number of cells and volume required to seed into a T75 flask. CHO-K1 K_V11.1 (hERG) cell doubling time is ~24h. A confluent T75 flask normally yields ~$10x10^6$ cells. We recommend to seed $1 X 10^6$ cells for a T75 flask.
14. Add 15 mL of complete cell culture medium into a new T75 flask, followed by addition of the appropriate volume of cell suspension. Transfer the flask to a tissue culture incubator, and incubate the cells at 37°C and 5% CO_2.

D. Cryopreservation

1. Harvest cells according to the description in **section C** Cell Passage **step 1 - 9**.
2. Set aside a small fraction of the suspended cells (100 µL or less) in a separate tube for cell counting.
3. Count cells, calculate the concentration of cells and the total number of cells in the original 15 mL conical tube.

Cell Culture Protocol Cont.

4. Centrifuge the 15 mL conical tube containing cells at 500xg for 5 min at 25°C.
5. After centrifugation, discard the supernatant, being careful not to disturb the cell pellet.
6. Based on the total cell number calculated in **Step 3**, resuspend the cells to the desired concentration (e.g. 2.0 x 10^6 cells/mL) in Bambanker serum free cell freezing medium.
7. Aliquot 1 mL of the cell suspension into each of the labeled 2 mL cryovials. Seal the cryovials tightly.
8. Freeze cells in a -80°C freezer at a controlled rate of -1°C/minute overnight in a commercially-available freezing container.
9. The following day, transfer the vials into the vapor phase of liquid nitrogen for long-term storage.

Functional Validation

The biological function of $K_V11.1$ channels were validated by channel blocker terfenadine using ION's Thallium Flux assay. Terfenadine is a highly selective blocker that interacts with $K_V11.1$ residues inside the pore. The reported IC50 of terfenadine is 204 nM. CHO-K1 $K_V11.1$ (hERG) cells are first incubated with Thallos AM dye solution for 1 hour. Then cells are treated with various doses of Terfenadine for 15 min. For the assay readout, high concentration potassium buffer is added to induce voltage change and activate the $K_V11.1$ channels. While the channels open, extracellular Tl^+ ions flux into the cells and bind to the Thallos AM dye to emit fluorescence signals. Fluorescence signals are first collected for 20 sec as the baseline, and continue to be collected for an extra 280 sec after the high potassium thallium stimulus solution addition (Figure 1). V_{max} is calculated as the slope of the first 10 time points right after the stimulus solution addition. Dose response curves were plotted as Log terfenadine concentration against V_{max}; generating an IC_{50}: 176 nM which is consistent to the reported value.



Figure 1. Terfenadine Dose Response Curve kinetic data. Thallium flux assay was performed using FlexStation 3 kinetic plate reader with excitation wavelength 490 nm and emission wavelength 520 nm. Baseline RFUs were collected for 20s, then TSS was added to the cell plate and data collection was continued for additional 280s. Fluorescence signals were normalized against the baseline as F/F_0. V_{max} was calculated as the slope of the first 10 time points right after the high potassium thallium stimulus solution addition.



Figure 2. Terfenadine Dose Response Curve. Thallium flux assay was performed using FlexStation 3 kinetic plate reader with excitation wavelength 490 nm and emission wavelength 520 nm. CHO-K1 Kv11.1 (hERG) cells were treated with potassium channel inhibitor Terfenadine at the highest concentration of 10 µM. Dose response curves were plotted as Log terfenadine concentration against V_{max}; generating an IC_{50}: 176 nM.

Vector and Sequence

Vector description

Mammalian Gene Expression PiggyBac Vector, pRP[Exp]-Puro-CAG>hKCNH2[NM_000238.4]

hKCNH2 sequence (NM_000238.4)

MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVMQRPCTCDFLHGPRTQRRAAAQIAQALLGAE
ERKVEIAFYRKDGSCFLCLVDVVPVKNEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRAKTFRLKLPALLALTARESS
VRSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSPPRSAPGQLPSPRAHSLNPDASGSSCS
LARTRSRESCASVRRASSADDIEAMRAGVLPPPPRHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDRE
IIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIYTAVFTPYSAAFLLKETEEGPPATECGYAC
QPLAVVDLIVDIMFIVDILINFRTTYVNANEEVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLDRYS
EYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSSGLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPN
TNSEKIFSICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGFPECLQ
ADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGK
SNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRRTDKDTEQPGEVSA
LGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSSPRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVS
NIFSFWGDSRGRQYQELPRCPAPTPSLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSAVTTP
GPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPGQLGALTSQPLHRHGSDPGS

References

1. Kim MD, Nimigean CM. Voltage-gated potassium channels: a structural examination of selectivity and gating. *Cold Spring Harb Perspect Biol*. **2016**, 8(5): a029231.
2. Alexander SP, Striessnig J, Kelly E, Marrion, NV, Peters JA, Faccenda E, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: voltage-gated ion channels. *Br. J. Pharmacol.* **2017**, 174, S160–S194.
3. Wulff H, Castle NA, and Pardo LA, Voltage-gated potassium channels as therapeutic target. *Nat. Rev. Drug Discov*. **2009**, 8(12), 982-1001.
4. Sanguinetti MC, Tristani-Firouzi M, hERG potassium channels and cardiac arrhythmia. *Nature*, **2006**, 440(7083), 463-469.
5. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. *Cell*, **1995**, 81(2), 299–307.
6. Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, Lipska BK, Hyde TM, Song J, Rujescu D, et. al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. *Nat. Med.* **2009**, 15(5), 509-518.
7. Arcangeli A, Expression and role of hERG channels in cancer cells. *Novartis Found. Symp*. **2005**, 266, 225-232.
8. Maly J, Emigh AM, DeMarco KR, Furutani K, Sack JT, Clancy CE, Vorobyov I, Yarov-Yarovoy V. Structural modeling of the hERG potassium channel and associated drug interactions. *Front. Pharmacol*. **2022**, 13:966463.
9. Crumb WJ, Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. *J. Pharmacol. Exp. Ther.* **2000**, 292(1), 261-264.

Limited Use License Agreement

Cell Line Terms and Conditions are explicitly accepted upon purchase. An additional agreement is needed for commercial use. These cells are sold under a non-transferable, limited use license to use the cells and their progeny in your immediate laboratory, for research use only. Commercial use of the cells is not permitted under this license. This license does not permit you to share, transfer, distribute, sell, sublicense, or otherwise make the cells available for use to other researchers, laboratories, departments, research institutions, hospitals, universities, CROs, or biotech companies. The license does not permit use of the cells in humans or for therapeutic or drug use. Inappropriate use or distribution of the cells will result in revocation of this license and result in an immediate cease of sales and distribution of ION Biosciences products to your laboratory.

ION Biosciences does not warrant the suitability of the cells for any particular use, and does not accept any liability including direct, indirect, consequential, or incidental damages in connection with the handling or use of the cells. Modifications of the cells not discussed herein, transfer to another facility, or commercial use requires a separate license and additional fees. Commercial use means any activity by a party for consideration and may include, but is not limited to (1) use of the product or associated components to provide a service, information or data to a third party and/or (2) resale of the product or associated components, whether or not such product or its components are resold for use in research. Contact sales@ionbiosciences.com for details.